compromise treatment continuation. Here we report our experience in patients with NSCLC, the incidence of irAEs and its correlation with efficacy. Method: We have retrospectively analyzed 101 patients with advanced NSCLC receiving ICIs in our institution from March 2014 to January 2018. IrAEs were graded following CTCAE v4.0. Kaplan Meier and log-rank tests were used to evaluate progressionfree (PFS) and overall survival (OS). Analyses were performed using SPSS v24 package. Result: Median age was 66.4 [37-85] years, 74.3% were male. 33 (32.7%) patients presented squamous and 68 (67.3%) non-squamous histology. Most frequent ICIs were nivolumab (50%), pembrolizumab (31%) and atezolizumab (16%), used as monotherapy (79.2%) or in combination with chemotherapy (20.8%). 37.6% patients were treated with ICIs in first line setting, while 62.4% in second or beyond. Median duration of treatment was 2.7 [0.6-26.2] months. 61 (60.4%) patients developed 106 irAEs, with a mean of 1.02 [0-4] irAEs per patient. Most frequent irAEs were rash (24.5%), pruritus (22.6%), diarrhea (21%), arthritis (8.5%), hypothyroidism (7.6%), hyperthyroidism (2.9%), hepatitis (2.9%) and pneumonitis (2%). 8 (7.5%) patients experienced grades (G) 3-4 irAEs: 1 G3 pneumonitis, 4 G3 diarrhea, 1 G3 mucositis, 1 G3 nephritis and 1 G3 hemolytic anemia. One treatment-related death due to pneumonitis was reported. Patients receiving ICIs in second line or beyond experienced significantly less irAEs (54.1%) than those treated in first line (73.7%), p 0.04. 47 (46.5%) patients received systemic corticosteroids during immunotherapy, 29.8% for irAEs management. 11 patients (10.9%) discontinued treatment due to irAEs. At the time of data analysis, 86.8% of irAEs had improved. With a median follow-up of 8.9 [0.6-48.2] months, median OS was superior in patients experiencing irAEs: not reached (NR) vs 7.8 [95%CI, 5.2-10.5] months (p 0.001). Similarly, PFS was significantly longer: 6.2 [95%CI, 2.3-10.1] vs 2.7 [95%CI, 1.8-3.5] months (p <0.0001). OS was higher in patients who did not receive steroids during ICIs therapy: NR vs 9.9 [95%CI, 6.8-13.0] months (p 0.024). No association was found between efficacy and the use of antibiotics in the 3 months before first ICIs injection or during treatment. Conclusion: In our series, the presence of irAEs in patients with advanced NSCLC treated with ICIs was associated with efficacy in terms of PFS and OS. A negative correlation between usage of systemic corticosteroids and outcomes was found.
Background: Mutations in LKB1/STK11 may predict a poor response to immunotherapy in NSCLC. We previously showed that pretreatment neutrophil-to-lymphocyte ratio (NLR) >5 predicted a poor response to immunotherapy in NSCLC. We evaluated the impact of STK11 mutation (MT) alone, and co-existing MTs in KRAS and TP53 on outcomes in patients (pts) treated with immunotherapy at the University of Pennsylvania. The role of NLR was also evaluated. Method: Patients with metastatic NSCLC that underwent NGS and who received 2 nd -line immunotherapy were identified (2/2013 e 12/2016). Patient demographics, tumor characteristics, and outcomes were analyzed from the electronic medical record. Chi-square and the Wilcoxon Rank-Sum test were used to assess correlation between NLR and MT status. Median overall survival (mOS) and median progression free survival (mPFS) times are estimated from Kaplan-Meier curves. A Cox proportional hazard model (HR) was used to assess the effect of mutation status on survival outcomes. Result: 110 pts were included with the following MT status: 5 STK11, 16 KRAS, 29 TP53, 13 KRAS/TP53, 7 KRAS/STK11, 9 TP53/STK11, 7 KRAS/TP53/STK11, 24 no STK11, KRAS or TP53 MT. In univariate and multivariable analyses, STK11 MT was not independently associated with mPFS or mOS after immunotherapy. Among pts with TP53 MT, the presence of a STK11 MT was associated with improved mPFS (4.3 vs. 2 mo, HR 0.416, p¼0 .035, (95% CI 0.18 e0.94)) and statistically similar mOS (13.1 vs 6.8 mo, HR 0.43, p¼0.09 (95%CI 0.16e1.14)) compared with STK11 wild type (WT). Conversely, among pts with KRAS MT, the presence of a STK11 MT was associated with similar mPFS (2.2 vs 2.8 mo, HR 1.64, p¼0.247 (95% CI 0.7e3.8)) and mOS (3.5 vs 7.7 mo, HR 2.3, p¼0.09 (0.16e1.14)) compared with STK11 WT. NLR did not correlate with MT status. After stratifying for NLR (<5 and >5), the effect of STK11 MT on mOS in the TP53 MT group was amplified in pts with NLR<5 (n¼46, HR 0.05, p¼0.021, 95% CI 0.004-0.63) compared to TP53 MT with STK11 WT (HR 4.3, p¼0.036 (95% CI 1.1-16.9)). Conclusion: STK11 mutation status alone does not correlate with pre-treatment NLR and is not independently associated with survival outcomes after immunotherapy. PFS following immunotherapy is improved in patients with co-existing TP53 and STK11 MT compared to STK11 WT. An OS benefit after immunotherapy is amplified in patients with NLR<5, TP53 MT, and STK11 co-MT. * Authors Marmarelis and Bange contributed equally Keywords: Immunotherapy, STK11, TP53 P1.01-65 PII of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (>¼75) Non-Squamous NSCLC (LOGIK1201) postoperative recurrence, age 75 years, PS 0-1, adequate bone marrow function. Patients were randomly assigned in a 1:1 ratio to P or P/B. Primary endpoint was PFS. Secondary were RR, OS, toxicity and cost-effect. Stratified log-rank test was used. Assuming PFS of median 3.3 (P) and 7.4 (P/B) months, significance level bilateral 20%, power 80%, estimated required number was 32 and target sample size was set 40. Result: Forty-one patients from 12 institutions were enrolled between 8/31/2012 and 6/30/2016 and 40 patients (P 20, P/B 20) were assessable. Patients' characteristics were as follows: male/female ¼ 23/17; median age (range) ¼ 78 (75-83); stage IIIB/IV/postOp ¼ 1/ 30/9; PS 0/1 ¼ 11/29; all adenocarcinoma. The median PFSs (95%CI) were 5.4 (3.0-7.4) and 5.5 (3.6-9.9) months, respectively, and there is no significant difference (p¼0.66). RR was significantly higher in P/B (15% vs. 55%, p¼0.0146) and there was no significant difference in OS (median 16.0 vs. 16.4 months, p¼0.58). G3/4 leukopenia, neutropenia, thrombocytopenia and fatigue (%) were 10, 20, 5, 25 and 30, 55, 5, 45, respectively. Costs were higher in P/B (median 1,522,008 vs. 3,368,428 JPY, p¼0.01). No treatment-related deaths occurred. Conclusion: P showed similar PFS and OS with favorable toxicity and low cost compare with P/B in elderly (>¼75) patients with NSqNSCLC. Keywords: elderly NSqNSCLC, randomized phase II study, pemetrexed and bevacizumab P1.01-66 Randomized Phase II Evaluating EGFR-TKI Associated with Anti-Estrogen in Women with Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial Background: The incidence of lung cancer is increasing dramatically in women with recent findings as the preferential involvement of the EGFR pathway and the potential impact of hormonal factors in women. Preclinical data have shown that the combination of an EGFR-TKI with an anti-estrogen could overcome resistance to EGFR-TKI. Method: IFCT-1003 LADIE Trial was a 2x2 arms parallel open-label randomized phase II trial. PS 0-2 post-menopausal women with advanced stage lung adenocarcinoma were treated with gefitinib (G 250 mg/day) vs. G + fulvestrant 500 mg / month with a supplementary dose at day 15 (G+F) in the EGFR mutated group (EGFR+) in 1st or 2nd line setting or with erlotinib (E 150 mg/day) vs. E + fulvestrant (E+F) in the EGFR wild-type group (EGFR WT) in 2nd or 3rd line setting until progression or unacceptable toxicity. Primary objective was progression-free survival (PFS) at 3 and 9 months for EGFR WT and EGFR+ patients, respectively. Result: From 02/2012 to 03/2017, 204 pts (G 104, G+F 100) and 175 (E 87, E+F 88) were enrolled in the EGFR+ and EGFR WT cohorts respectively. The median number of fulvestrant injections was 10 in the G+F group and 3 in the E+F group. The tolerance was correct (grade 3/4: 24.2% in the G+F group vs 21.3% in the G group, 16.0% in the E+F group vs 13.8% in the E group) and no treatment-related death. In the EGFR+ cohort, the primary endpoint was reached as 54 pts in the G+F group were non-progressive at 9 months. Nevertheless, addition of F to G was not associated with significant better PFS (9.9 vs 10.1 months) or OS (22.1 vs 29.9 months). In the EGFR WT cohort, the primary endpoint was not reached as 29 patients were non-progressive at 3 months. Here also, addition of F to E was not associated with better outcome (PFS 1.8 vs 2.0 and OS 10.0 vs 7.3 months). No PFS difference was observed in the subgroup of patients with positive staining for REa. Conclusion: Addition of fulvestrant to EGFR-TKI is feasible and is associated with good PFS in the EGFR mutated group. Nevertheless, the lack of benefit associated with the combination of fulvestrant to EGFR-TKI does not support its future development in a phase 3 trial in women with NSCLC. Keywords: fulvestrant, EGFR-TKI, NSCLC P1.01-67 Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients
